The coronavirus disease 2019 (COVID-19) pandemic has disrupted polio immunization programs worldwide. The consequences of these programs' suspension were not fully presented during the COVID-19 pandemic, as some take time to present in a population. We conducted a narrative review to provide a perspective of current literature on the effect of the COVID-19 pandemic on efforts made for poliomyelitis eradication. An overview of potential risks of polio outbreaks and areas where wild and vaccine-derived polioviruses have been reported will be presented in this review. Decreased vaccination rate, human and financial resources diversion to tackle COVID-19, and polio surveillance suspension during the COVID-19 pandemic contributed to creating an immunity gap and increasing the risk of polio outbreaks in at-risk areas. Approaches for integrating immunization efforts with educating the general population, engaging religious leaders, and solving gender disparities to fill the gap that have been made during the pandemic. The path to control polio should engage different levels of policy-making, and governments of affected countries play crucial roles. Strong interdisciplinary collaboration and dedicated efforts are needed to inform policymakers and encourage the public to follow vaccination programs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/20477724.2024.2439740 | DOI Listing |
Alzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Participant dropout from study treatment in a clinical trial can leave a trial underpowered, produce bias in statistical analysis, and limit interpretability of study results. Retaining participants in clinical trials for the full study duration is therefore as important as participant recruitment. This analysis aims to identify the baseline characteristics of participants who discontinued during the blinded phase of one of the first and largest preclinical AD trial completed to date, the Anti-Amyloid treatment in Asymptomatic AD (A4) Study.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, Irvine, Irvine, CA, USA.
Background: Recruitment challenges in people with and without Down syndrome (DS) can delay research progress and risk sample bias. This study identified and quantified differences in research attitudes across populations of research enrollment decision-makers for individuals with and without DS.
Method: We compared scores on the Research Attitudes Questionnaire (RAQ) of individuals enrolled in two recruitment registries: the UCI Consent to Contact [C2C (N = 4818)] and DS-Connect (N = 976).
Alzheimers Dement
December 2024
Singapore General Hospital, Singapore, Singapore, Singapore.
Background: With the advent of new media, more people - possibly including caregivers of persons with dementia - are turning to social media platforms to share their thoughts and emotions related to personal life experiences. This may potentially serve as an opportunity to leverage on social media to gain insights into the key issues faced by dementia caregivers. We examined salient concerns of dementia caregivers through Twitter posts, aiming to shed light on how to better support and engage such caregivers.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Pittsburgh, Pittsburgh, PA, USA.
Background: The COVID-19 pandemic had a major impact on healthcare, contributing to a mass exodus of the workforce. This poses a concern for Alzheimer's disease and related dementias (ADRD) care, which benefits from consistent care routine and staff that know the resident. Therefore, it is important to understand nursing home staff perspectives on maintaining high staff morale, which impacts recruitment, retention, and care quality.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Tulane University, New Orleans, LA, USA.
Background: Vascular dementia (VaD), the second most common cause of dementia, is characterized by cognitive decline due to reduced cerebral blood flow and blood-brain barrier disruption. Current evidence demonstrates that not only are VaD patients at higher risk of severe COVID-19 illness and mortality, but also that pre-existing cognitive dysfunction/dementia is associated with increased COVID-19 incidence. Conversely, SARS-CoV-2 infection alone worsens dementia-related mild cognitive impairment (MCI) and increases risk of cognitive decline, supported by similar fMRI findings demonstrating hypoperfusion.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!